Zhong Ji Longevity Science Group Insiders Up HK$7.7m On HK$16.5m Investment

Simply Wall St

Insiders who purchased Zhong Ji Longevity Science Group Limited (HKG:767) shares in the past 12 months are unlikely to be deeply impacted by the stock's 15% decline over the past week. After taking the recent loss into consideration, the HK$16.5m worth of stock they bought is now worth HK$24.2m, indicating that their investment yielded a positive return.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

We've discovered 4 warning signs about Zhong Ji Longevity Science Group. View them for free.

Zhong Ji Longevity Science Group Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when insider Jianyong Wang bought HK$10.0m worth of shares at a price of HK$0.21 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of HK$0.32. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

In the last twelve months Zhong Ji Longevity Science Group insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Check out our latest analysis for Zhong Ji Longevity Science Group

SEHK:767 Insider Trading Volume May 23rd 2025

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Zhong Ji Longevity Science Group

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Zhong Ji Longevity Science Group insiders own 48% of the company, worth about HK$82m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Does This Data Suggest About Zhong Ji Longevity Science Group Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. It would be great to see more insider buying, but overall it seems like Zhong Ji Longevity Science Group insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 4 warning signs for Zhong Ji Longevity Science Group (1 shouldn't be ignored) you should be aware of.

Of course Zhong Ji Longevity Science Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Valuation is complex, but we're here to simplify it.

Discover if Zhong Ji Longevity Science Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.